268 related articles for article (PubMed ID: 11709563)
1. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
McGinn CJ; Zalupski MM; Shureiqi I; Robertson JM; Eckhauser FE; Smith DC; Brown D; Hejna G; Strawderman M; Normolle D; Lawrence TS
J Clin Oncol; 2001 Nov; 19(22):4202-8. PubMed ID: 11709563
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
[TBL] [Abstract][Full Text] [Related]
3. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
[TBL] [Abstract][Full Text] [Related]
5. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
[TBL] [Abstract][Full Text] [Related]
6. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Robertson JM; Margolis J; Jury RP; Balaraman S; Cotant MB; Ballouz S; Boxwala IG; Jaiyesimi IA; Nadeau L; Hardy-Carlson M; Marvin KS; Wallace M; Ye H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e187-92. PubMed ID: 21549514
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
Ben-Josef E; Schipper M; Francis IR; Hadley S; Ten-Haken R; Lawrence T; Normolle D; Simeone DM; Sonnenday C; Abrams R; Leslie W; Khan G; Zalupski MM
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1166-71. PubMed ID: 22543215
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
Epelbaum R; Rosenblatt E; Nasrallah S; Faraggi D; Gaitini D; Mizrahi S; Kuten A
J Surg Oncol; 2002 Nov; 81(3):138-43. PubMed ID: 12407726
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162
[TBL] [Abstract][Full Text] [Related]
15. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
Talamonti MS; Catalano PJ; Vaughn DJ; Whittington R; Beauchamp RD; Berlin J; Benson AB
J Clin Oncol; 2000 Oct; 18(19):3384-9. PubMed ID: 11013279
[TBL] [Abstract][Full Text] [Related]
16. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Yavuz AA; Aydin F; Yavuz MN; Ilis E; Ozdemir F
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):974-81. PubMed ID: 11704320
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.
Blackstock AW; Bernard SA; Richards F; Eagle KS; Case LD; Poole ME; Savage PD; Tepper JE
J Clin Oncol; 1999 Jul; 17(7):2208-12. PubMed ID: 10561277
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
[TBL] [Abstract][Full Text] [Related]
20. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Aparicio J; García-Mora C; Martín M; Petriz ML; Feliu J; Sánchez-Santos ME; Ayuso JR; Fuster D; Conill C; Maurel J
PLoS One; 2014; 9(1):e82209. PubMed ID: 24416138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]